ASPR Newsroom

HHS sponsors new formulation of world’s first approved smallpox drug

Smallpox can damage the throat making it nearly impossible to swallow pills. BARDA will purchase the antiviral smallpox medication called TPOXX in pill form and support the development of an intravenous (IV) formulation of the drug. The IV formulation will be used to expand health security and prepare for the potential use of smallpox in a biothreat.
HHS enlists MediWound to develop treatment for sulfur mustard injury

Mustard agents have been used in conflicts for over a 100 years and there are no approved treatments. BARDA is supporting the development of a new treatment for skin injuries caused by sulfur mustard, potential terrorism threat.
From the ASPR Blog: BARDA and its partners bring new ammunition to the battle against superbugs

Pathogens causing serious infections can become resistant to antibiotics, threatening health security. Learn how BARDA is driving innovation in antibiotic development & partnering with industry to build a portfolio of products that could be used to save lives when disaster strikes.
BARDA Industry DAY: Lightning Talks
APPLY NOW!

BARDA is excited to debut a new opportunity at this year’s BARDA Industry Day, to be held October 29-30, 2018 at the Grand Hyatt in Washington, DC. We will host Lightning Talks, a showcase for pharmaceutical companies, biotech and other innovators to provide an introduction to their product and approach.
ASPR’s Vision For Building Readiness: Sustaining Robust and Reliable Public Health Security Capabilities

HHS’ Vision for Healthcare Preparedness is a multi-part blog series that describes ASPR’s four pillars to achieving national health security. This blog focuses on sustaining public health security capabilities.